Filing Flows › Immucell (ICCC) › Q1 2026
Immucell (ICCC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Immucell (ICCC) reported revenue of $10.4M for the first quarter 2026 (Q1 2026), +28% from a year earlier and +36% from the quarter before. Operating margin was 19.0%, net earnings $1.9M (18.7% of revenue).
Immucell, Q1 2026: revenue $10.4M (+28% year over year), operating margin 19.0%, net earnings $1.9M, operating cash flow $3.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | +36% | +28% |
| Gross profit | $4.7M | +60% | +39% |
| Operating profit | $2.0M | — | +76% |
| Net earnings | $1.9M | — | +34% |
| Operating cash flow | $3.6M | +640% | +127% |
| Free cash flow | $3.4M | +995% | +173% |
What changed
Revenue was $10.4M in Q1 2026, up 28% year over year and up 36% from the previous quarter.
Gross margin was 45.0%, up 3.4 points from Q1 2025. Operating profit was $2.0M, a 19.0% margin (up 5.2 points year over year). Of the extra revenue versus Q1 2025, 37% reached operating profit, above the 14% margin then. Operating expenses grew 20% against revenue growth of 28%. The fastest-growing cost line was General & admin (+83%). Net earnings were $1.9M, up 34% year over year. The effective tax rate was 0.6%.
Operating cash flow was $3.6M (up 127% year over year), 184% of net earnings. Non-cash charges added back $531K of depreciation and amortization and $138K of share-based compensation. Working capital and other items added $1.0M. Capital expenditures of $177K left free cash flow of $3.4M.
Questions
What was Immucell's revenue in the first quarter 2026?
Immucell (ICCC) reported revenue of $10.4M for the first quarter 2026 (Q1 2026), +28% from a year earlier and +36% from the quarter before.
Was Immucell profitable in the first quarter 2026?
Operating profit was $2.0M (19.0% of revenue) and net earnings $1.9M.
Source: Immucell 10-Q on SEC EDGAR.